KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CRISPR Therapeutics AG (CRSP) Current Assets (2016 - 2025)

CRISPR Therapeutics AG (CRSP) has disclosed Current Assets for 11 consecutive years, with $2.0 billion as the latest value for Q4 2025.

  • Quarterly Current Assets rose 2.51% to $2.0 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $2.0 billion through Dec 2025, up 2.51% year-over-year, with the annual reading at $2.0 billion for FY2025, 2.51% up from the prior year.
  • Current Assets hit $2.0 billion in Q4 2025 for CRISPR Therapeutics AG, up from $1.9 billion in the prior quarter.
  • In the past five years, Current Assets ranged from a high of $2.6 billion in Q2 2021 to a low of $1.7 billion in Q2 2025.
  • Historically, Current Assets has averaged $2.0 billion across 5 years, with a median of $1.9 billion in 2022.
  • Biggest five-year swings in Current Assets: surged 171.43% in 2021 and later dropped 23.35% in 2022.
  • Year by year, Current Assets stood at $2.4 billion in 2021, then decreased by 23.35% to $1.9 billion in 2022, then increased by 2.97% to $1.9 billion in 2023, then grew by 1.52% to $1.9 billion in 2024, then grew by 2.51% to $2.0 billion in 2025.
  • Business Quant data shows Current Assets for CRSP at $2.0 billion in Q4 2025, $1.9 billion in Q3 2025, and $1.7 billion in Q2 2025.